PRESS RELEASE: Lu AA21004 Shows Highly Significant Results in Clinical Phase II Trial

Lu AA21004 Shows Highly Significant Results in Clinical Phase II Trial

COPENHAGEN, Oct. 2, 2007-H. Lundbeck A/S today announced positive headline results from a newly unblinded proof of concept clinical study with the compound Lu AA21004 for the treatment of Major Depressive Disorder. 

The clinical trial was a multicenter, double-blind, placebo-controlled trial including 426 patients with major depression. Lu AA21004 showed highly significant improvements on the primary efficacy endpoints with both 5 and 10 mg compared to placebo and had an attractive safety profile.

"We are pleased that the encouraging results from this proof of concept study confirm our experimental expectations of Lu AA21004 as a potent and well tolerated new drug for the treatment of major depression," says Anders Gersel Pedersen, Head of Development at Lundbeck and continues: "Lu AA21004 is the most advanced project within the new bis-aryl-sulphanyl amine class of compounds for the treatment of mood disorders and anxiety, and we look forward to further exploiting the potential of these novel projects."

Lu AA21004 is jointly being developed by H. Lundbeck A/S and Takeda Pharmaceutical Company Limited. Following analysis of the phase II data, Lundbeck and Takeda will plan the next steps in the development of Lu AA21004.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.